Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study
Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study
DJ Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study
By Chris Wack
Sutro Biopharma Inc. said Thursday it has dosed the first patient in the dose-expansion cohort of its Phase 1 STRO-002 study.
STRO-002 is a folate receptor alpha targeting antibody-drug conjugate for the potential treatment of ovarian cancer.
The company said the dose-expansion cohort will assess the efficacy, safety and tolerability of STRO-002 at 4.3 and 5.2 mg/kg, given every three weeks in patients with ovarian cancer. The dose-expansion cohort for folate receptor alpha-selected endometrial cancer is planned for later this year.
Sutro said it plans to expand the study to 35 clinical sites in the U.S. and Europe. The dose-expansion study includes two patient cohorts, advanced epithelial ovarian cancer and endometrial cancer.
Sutro Biopharma shares were up 17% to $30.86 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 21, 2021 08:16 ET (13:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study
DJ Sutro Biophma劑量首例卵巢癌治療研究
By Chris Wack
克里斯·瓦克(Chris Wack)著
Sutro Biopharma Inc. said Thursday it has dosed the first patient in the dose-expansion cohort of its Phase 1 STRO-002 study.
Sutro Biophma Inc.週四表示，它已經給其1期Stro-002研究的劑量擴展隊列中的第一名患者開了藥。
STRO-002 is a folate receptor alpha targeting antibody-drug conjugate for the potential treatment of ovarian cancer.
STRO-002是一種葉酸受體α靶向抗體-藥物結合物，可用於卵巢癌的潛在治療。
The company said the dose-expansion cohort will assess the efficacy, safety and tolerability of STRO-002 at 4.3 and 5.2 mg/kg, given every three weeks in patients with ovarian cancer. The dose-expansion cohort for folate receptor alpha-selected endometrial cancer is planned for later this year.
該公司表示，劑量擴大隊列將評估Stro-002的有效性、安全性和耐受性，分別為4.3和5.2 mg/kg，用於卵巢癌患者，每三週服用一次。葉酸受體α選擇的子宮內膜癌的劑量擴展隊列計劃在今年晚些時候進行。
Sutro said it plans to expand the study to 35 clinical sites in the U.S. and Europe. The dose-expansion study includes two patient cohorts, advanced epithelial ovarian cancer and endometrial cancer.
Sutro表示，計劃將這項研究擴大到美國和歐洲的35個臨牀地點。劑量擴張研究包括兩個患者隊列，晚期上皮性卵巢癌和子宮內膜癌。
Sutro Biopharma shares were up 17% to $30.86 in premarket trading.
Sutro Biophma股價在盤前交易中上漲17%，至30.86美元。
Write to Chris Wack at chris.wack@wsj.com
寫信給克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道瓊通訊社
January 21, 2021 08:16 ET (13:16 GMT)
2021年1月21日東部時間08：16(格林尼治標準時間13：16)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧